XeroThera has developed breakthrough technologies for tissue engineering and the controlled and targeted delivery of drugs and biological molecules. The technology is the result of twenty years of fundamental studies on sol gel processed, nanoporous, oxide-based materials in academic laboratories at the University of Pennsylvania, Philadelphia.

XeroThera’s unique delivery concepts make it possible to treat conditions that currently defy solutions. It has formulated a pipeline of product concepts that address the prevention and treatment of surgical infections, bone infections, and resistant (“MRSA”) infection; it can also develop tissue engineering scaffolds, and address surgical pain treatment and diabetes wound treatment.

XeroThera

Org chart

Teams

Offices